Nikki A DeAngelis

Title: **Nikki A. DeAngelis: Innovating in Antibody Research**

Introduction

Nikki A. DeAngelis, based in Spring House, Pennsylvania, is a distinguished inventor recognized for her significant contributions to the field of biochemistry. With a total of two patents to her name, she has made remarkable strides in the development of antibodies that target critical immune checkpoint proteins. Her work stands at the forefront of innovation in therapeutic solutions for various diseases.

Latest Patents

DeAngelis's latest patents focus on antibodies that specifically bind to PD-1 and TIM-3. These patents detail the design and usage of antibodies that target these proteins, which play essential roles in regulating immune responses. The inventions include polynucleotides encoding the antibodies or their fragments and outline the methods of making and using these innovative antibodies for therapeutic applications. The significance of these inventions lies in their potential to enhance cancer immunotherapy and address other immune-related disorders.

Career Highlights

Nikki A. DeAngelis currently works at Janssen Biotech, Inc., a leading company in the biopharmaceutical industry. Her role involves advancing research in antibody development, contributing to the company's mission of creating transformative therapies. With her expertise, DeAngelis has positioned herself as a key player in the realm of antibody innovation, driving forward essential projects that hold the promise of improving patient outcomes.

Collaborations

Throughout her career, DeAngelis has collaborated with notable professionals in her field, including Nina Chi Sabins and Sandra Santulli-Marotto. These collaborations enhance the research and development efforts within Janssen Biotech, as the combined expertise of these inventors leads to the exploration of new ideas and solutions in antibody therapies.

Conclusion

In summary, Nikki A. DeAngelis is a pioneering inventor whose work focuses on innovative antibody research. Her patents for antibodies binding to PD-1 and TIM-3 represent significant progress in therapeutic development. As she continues to contribute to the field through her role at Janssen Biotech, her research will likely have a lasting impact on the treatment of various diseases, highlighting the importance of collaboration and innovation in the scientific community.